RecruitingCarcinoma, HepatocellularLiver Cell Carcinoma
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participants and optimize local control.
Sponsor: Rutgers, The State University of New Jersey
You may qualify if…
- ✓ Each patient eligible to participate in this study must meet all the following criteria:
- ✓ 1. Written informed consent
- ✓ 2. Primary diagnosis of HCC, planned to receive radiation, treatment naïve to systemic therapy for HCC, prior TACE permitted
- ✓ 3. Hepatocellular carcinoma diagnosis by histologic findings and/or imaging criteria of LI-RADS 5
- ✓ 4. Eastern Cooperative Oncology Group performance status score of 0-2
- ✓ 5. Age\>/=18 years
- ✓ 6. Child-Pugh class A liver function or B7, BCLC A-C or deemed not a candidate for surgery or liver transplantation
- ✓ 7. No extrahepatic metastasis detected on CT chest with or without IV contrast, abdomen and pelvis with IV and oral contrast (triphasic-if feasible based on kidney function), or MRI abdomen/liver and chest CT.
You may not qualify if…
- ✕ <!-- -->
- ✕ 1. Prior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
- ✕ 2. Prior selective internal radiotherapy/hepatic arterial Yttrium therapy, at any time
- ✕ 3. Severe, active co-morbidity as per investigator
- ✕ 4. More than five discrete intrahepatic parenchymal foci of definite HCC or left/right or main portal vein thrombus
- ✕ 5. Direct tumor extension into the stomach, duodenum, small bowel or large bowel
- ✕ 6. Measurable common or main branch biliary duct involvement with HCC
- ✕ 7. Extrahepatic metastases or malignant nodes (that enhance with typical features of HCC) \> 3.0 cm, in sum of maximal diameters (e.g. presence of one 3.4 cm metastatic lymph node or two 2 cm lung lesions).
Where it's recruiting
New Jersey
New Brunswick
New York
The Bronx
Source: ClinicalTrials.gov · NCT05366829 · last updated 2026-01-20